Parmax Pharma Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Parmax Pharma Ltd. on BSE

Load latest

Parmax Pharma Ltd.

24 Mar 2025

38.02

0.24%

SAST

Parmax Pharma Ltd - 540359 - Closure of Trading Window

BSE India

Pursuant to SEBI (PIT) Regulations, 2015, "trading window" for dealing in securities of the company for designated persons will remain closed from 1st April, 2025 till 48 hours after declaration of financial results for the quarter ending on 31st March, 2025.

pdf

Parmax Pharma Ltd.

14 Feb 2025

38.02

0.24%

Corp. Note

Parmax Pharma Ltd - 540359 - Integrated Filing (Financial)

BSE India

In accordance with amendments to the SEBI (LODR) Regulations, 2024 read with SEBI circular No. SEBI/HO/CFD-PoD2/CIR/P/2024/185 dated 31st December, 2024 read with BSE circular no. 20250102-4 dated 2nd January, 2025, the integrated filing of financial statements for the quarter ended on 31st December, 2024 is attached herewith.

pdf

Parmax Pharma Ltd.

14 Feb 2025

38.02

0.24%

Result

Parmax Pharma Ltd - 540359 - Financial Results For The Quarter Ended On 31St December, 2024

BSE India

Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015 the board of directors of the company at its meeting held today i.e. 14th February, 2025 inter alia considered and approved Unaudited financial results of the company for the quarter ended on 31 st December, 2024 along with Limited Review report provided by statutory auditors of the company.

pdf

Parmax Pharma Ltd.

14 Feb 2025

38.02

0.24%

Board Meeting

Parmax Pharma Ltd - 540359 - Board Meeting Outcome for Outcome Of Board Meeting

BSE India

Pursuant to the provisions of Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company at its meeting held today, i.e. November 14, 2024 inter alia has considered and approved: 1. The Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2024. The same has also been reviewed by the Audit Committee in its meeting held today. 2. B A Shah S R Mehta & Co., Statutory Auditors of the Company have carried out the Limited Review of the Unaudited Financial Results for the quarter and half year ended on September 30, 2024 and the Board has also taken on record their Limited Review Report on the said Results.

pdf

Parmax Pharma Ltd.

06 Feb 2025

38.02

0.24%

Board Meeting

Parmax Pharma Ltd - 540359 - Board Meeting Intimation for Intimation Of Board Meeting In Compliance …

BSE India

Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 ,inter alia, to consider and approve the Meeting of the Board of Directors of Parmax Pharma Limited will be held on Friday, 14th February, 2024 at 3:00 PM inter alia to consider, approve the Un-Audited Financial Results for the quarter ended 31st December, 2024 and to discuss any other matter with the permission of Board.

pdf

Parmax Pharma Ltd.

04 Jan 2025

38.02

0.24%

Company Update

Parmax Pharma Ltd - 540359 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2015 for the quarter ended on 31st December, 2024 received from M/S Purva Sharegistry India Pvt Ltd. Registrar and Share Transfer Agent of our company.

pdf

Parmax Pharma Ltd.

28 Dec 2024

38.02

0.24%

SAST

Parmax Pharma Ltd - 540359 - Closure of Trading Window

BSE India

Pursuant to Company''s code of practices and procedures and code of conduct to regulate, monitor and report trading in securities and SEBI (Prohibition of Insider Trading) Regulations, 2015, ''Trading Window'' for dealing in securities of the company for designated persons will remain closed from 1st january, 2025 till 48 hours after the declaration of financial results for the quarter ending on 31st December, 2024.

pdf

Parmax Pharma Ltd.

13 Dec 2024

38.02

0.24%

Corp. Note

Parmax Pharma Ltd - 540359 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / …

BSE India

Intimation regarding loss of share certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.

pdf

Parmax Pharma Ltd.

02 Dec 2024

38.02

0.24%

Company Update

Parmax Pharma Ltd - 540359 - Reason For Delay In Filing Financial Statements For The Quarter …

BSE India

we would like to inform you that the financial statements for the period ending on September 30, 2024 were duly prepared and approved at the scheduled meeting of Board of Directors held on Thursday, 14th November, 2024. We apologize for this delay in filing , due to circumstances beyond our control. We request you to condone this delay filing as all processes and approvals were completed within the required timeline.

pdf

Parmax Pharma Ltd.

15 Nov 2024

38.02

0.24%

Result

Parmax Pharma Ltd - 540359 - Financial Results For The Quarter And Half Year Ended On …

BSE India

As per regulation 30 and 33 of SEBI (LODR) Regulations, 2015 the board of directors at its meeting held on 14th November, 2024 inter alia considered and approved the Unaudited Financial Results for the quarter and half year ended on 30th September, 2024 along with the Limited Review Report provided by B A Shah S R Mehta, statutory Auditor of the company.

pdf

Is Parmax Pharma Ltd. worth buying?

4 Votes:

Buy 25.0%

Sell 25.0%

Hold 50.0%

30.90% Fall from 52W High

High vol. this week

Parmax Pharma Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Parmax Pharma Ltd. on BSE